Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TNON vs GRML: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TNON Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–3 Matrix Metrics)

TNON Overall Winner 6-Pillar Tally: TNON 3 – 1 GRML (2 Tie) Matrix Metrics: TNON 5 – 3 GRML

As of Nov 16, 2026, Tenon Medical, Inc. (TNON) is the stronger overall head-to-head candidate over GRML (GRML) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TNON carries a Unified Composite Score of 45.0/100 (HOLD) at $1.33 (N/M Forward P/E, -228.0% operating margin), whereas GRML carries 56.8/100 (HOLD) at $3.50 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While GRML currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. TNON 45.0/100 HOLD), TNON captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-228.0% vs. N/A operating margin) and revenue trajectory (+126.8% vs. N/A YoY).
  • Technical & Structure Timing Caution: TNON is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.5); meanwhile GRML trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TNON vs GRML
TNON NASDAQ Head-to-Head Winner
Tenon Medical, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.33
-5.32% 1D
Market Cap $3.8M
TTM Revenue $5.3M
Forward P/E N/M
Beta / 30D Vol -1.54β · 106% Vol
Unified Composite Score
45.0 / 100 HOLD
Tech 33.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -33.3%), weak momentum, RSI 27
RSI-14: 27.5 · SMA20: $1.96 · SMA50: $2.95
GRML US Equity
GRML
Institutional Equity
$3.50
-3.05% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -5.29β · 95% Vol
Unified Composite Score
56.8 / 100 HOLD
Tech 60.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 37
RSI-14: 37.5 · SMA20: $4.67 · SMA50: $6.11

6-Pillar Scorecard Institutional Category Breakdown (TNON 3 – 1 GRML)

Columns: Metric · TNON · GRML
1. Valuation Multiples TNON
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 1.5x N/M
2. Growth & Scale TNON
Revenue Growth (YoY) +126.8% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $5.3M N/A
Market Cap $3.8M N/A
3. Profitability & Quality TNON
Gross Margin 66.8% N/A
Operating Margin -228.0% N/A
Net Profit Margin -257.9% N/A
Return on Equity (ROE) -551.2% N/A
4. Balance Sheet & Cash Flow GRML
Cash Generation (TTM) -$12M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.0M Net Debt N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TNON (5) vs GRML (3)
Institutional Metric TNON GRML Criterion Row Edge
Market Capitalization
Scale
$3.8M N/A Larger Scale TNON
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+126.8% N/A Higher Growth TNON
Operating Margin (TTM)
Profitability
-228.0% N/A Higher Margin TNON
Net Profit Margin
Profitability
-257.9% N/A Higher Margin TNON
Return on Equity (ROE)
Capital Efficiency
-551.2% N/A Higher ROE TNON
52-Week Range Position
Momentum
7% ($0–$18) 18% ($0–$18) Stronger Trend GRML
Beta / 30D Volatility
Risk Regime
-1.54β · 106% Vol -5.29β · 95% Vol Lower Realized Risk GRML
Unified Institutional Score
Composite Signal
45.0 / 100 (HOLD) 56.8 / 100 (HOLD) Higher Composite GRML
Trailing 12M Revenue (USD)
Operating Scale
$5.3M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
66.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M EBITDA ($4.0M Net Debt) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GRML +8.89 pp
TNON: -50.56% · GRML: -41.67%
3M Horizon GRML +1837.2 pp
TNON: -75.5% · GRML: +1761.7%
6M Horizon GRML +797.35 pp
TNON: +93.87% · GRML: +891.22%
1Y Horizon GRML +582.06 pp
TNON: +65.8% · GRML: +647.86%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TNON vs GRML. Trailing 12-month operating profitability (TNON -228.0% vs GRML N/A) and valuation multiples (TNON N/M vs GRML N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TNON ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.3M
Gross Margin66.8%
Op. Margin-228.0%
ROE / Fwd P/E-551.2% · N/M
GRML ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TNON UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TNON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GRML UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GRML Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TNON Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $3.8M market capitalization and -228.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GRML Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TNON vs GRML Key Questions & Quantitative Answers

As of Nov 16, 2026, Tenon Medical, Inc. (TNON) is the stronger overall head-to-head candidate over GRML (GRML) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TNON carries a Unified Composite Score of 45.0/100 (HOLD) at $1.33 (N/M Forward P/E, -228.0% operating margin), whereas GRML carries 56.8/100 (HOLD) at $3.50 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While GRML currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. TNON 45.0/100 HOLD), TNON captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-228.0% vs. N/A operating margin) and revenue trajectory (+126.8% vs. N/A YoY). Technical & Structure Timing Caution: TNON is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.5); meanwhile GRML trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TNON leads the Growth & Scale pillar: TNON posts +126.8% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (66.8% gross margin, -228.0% operating margin), compared with GRML at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, TNON generates $5.3M in USD-normalized revenue versus N/A for GRML. In operating R&D and SG&A reinvestment, TNON deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GRML.

TNON screens cheaper on headline valuation multiples. TNON trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.5x EV/Revenue (unreported EBITDA margin), whereas GRML trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TNON (-551.2% ROE) versus GRML (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, TNON carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-1.54β · 106% Vol realized risk). By comparison, GRML carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-5.29β · 95% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.